During the ‘EPSCO’ Council meeting on 21 June, EU Member States are expected to discuss ways (incentives) to improve access to innovative and affordable medicines for patients and national healthcare systems.
These incentives are part of the European Commission’s proposals on pharmaceutical reform to make medicines “more accessible, more affordable and more innovative” (see EUROPE 13388/13).
During a meeting of the Committee of Permanent Representatives of the Member States to the EU (Coreper) on Wednesday 29 May, delegations took stock of progress on the pharmaceutical package (directive on the EU code relating to medicines and regulation laying down EU procedures for the authorisation and supervision of medicines).
A number of Member States took the floor briefly to stress the importance of not creating barriers to the internal market in this sector. A representative of the European Commission is said to have expressed concern at the slowness of the EU Council’s work on this pharmaceutical package.
Coreper also confirmed the agreement (see EUROPE 13400/15) on the regulation of certain in vitro diagnostic medical devices.
See the rules: https://aeur.eu/f/ceo (Original version in French by Lionel Changeur)